Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Physicians Committee for Responsible Medicine

T. J. Key

Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

Lp(a): When to Measure it and What to Do About it

Canadian Collaborative Research Network

M. O'Donoghue

Recent Cholesterol Guidelines and Integration into Clinical Practice

The North American Thrombosis Forum (NATF)

J. Plutzky, L. Braun, J. Ross

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Lipids Update: Current Guidelines for Lipid Management

Scripps Health

S. R. Mehta

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Directions of Cardiology in the Next Decade: 2022-2032

Houston Methodist DeBakey Heart and Vascular Center

E. Braunwald

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Tirzepatide Updates

Diana Isaacs

Weightloss in Menopause

Susan Brian

How Do I Reverse Coronary Plaque?

Scripps Health

C. J. Suhar

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg